RegenxBio raises $138.6M in IPO

Gene therapy play RegenxBio Inc. (NASDAQ:RGNX) gained $8.45 (38%) to $30.45 in its first day of trading after it raised $138.6 million through the sale of 6.3 million shares at $22 in an IPO underwritten by Morgan Stanley; BofA Merrill Lynch; Piper Jaffray; and Chardan Capital Markets. The IPO price valued the company at $557.7 million.

RegenxBio proposed the offering in August, when it said it would raise up to $100 million. It amended the offering Wednesday to raise up to $122.2 million through the sale of 5.6 million shares at $22, which would have valued the company at $541.3 million. ...